Sign In
Buy SCYX
$4.67
-0.430 (-8.43%)
At Close: Jun 03, 2026
Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates
09:56am, Thursday, 11'th May 2023
Scynexis (SCYX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.51 per share a year ago.
JERSEY CITY, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
Scynexis (SCYX) Inks Antifungal Drug Deal With GSK
01:47pm, Friday, 31'st Mar 2023
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive
Scynexis: Licensing Deal With GSK, Upgrading To A Hold Rating From A Sell
11:47am, Friday, 31'st Mar 2023
GSK and SCYNEXIS signed an exclusive licensing agreement for Brexafemme, an FDA-approved medicine for vulvovaginal candidiasis. GSK will pay SCYNEXIS $90 million upfront, with additional milestone pay
Penny Stocks: Technical Approach to Finding Opportunities
06:00am, Friday, 31'st Mar 2023
Use these tips to identify penny stocks opportunities The post Penny Stocks: Technical Approach to Finding Opportunities appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto
Why Is Scynexis (SCYX) Stock Up 69% Today?
10:26am, Thursday, 30'th Mar 2023
Scynexis (NASDAQ: SCYX ) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme. Brexafemme is an antifungal for the treatment of vulvovaginal candi
SCYNEXIS, Inc. (SCYX) Q3 2022 Earnings Call Transcript
10:52pm, Wednesday, 09'th Nov 2022
SCYNEXIS, Inc. (NASDAQ:SCYX ) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET Company Participants Debbie Etchison - Communications & IR Dr. Marco Taglietti - President & CEO Dr. David Ang
Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates
09:47am, Wednesday, 09'th Nov 2022
Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9
08:30am, Tuesday, 01'st Nov 2022
JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
Scynexis: No Compelling Reason To Invest
02:02am, Sunday, 30'th Oct 2022
Scynexis launched a product for VVC where there is no significant commercial demand. An additional indication in preventing VVC is not likely to significantly increase sales.
SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
08:30am, Tuesday, 11'th Oct 2022
JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
SCYNEXIS to Participate in Upcoming September Investor Conferences
08:30am, Friday, 09'th Sep 2022
JERSEY CITY, N.J., Sept. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resista
SCYNEXIS, Inc. (SCYX) CEO Dr. Marco Taglietti on Q2 2022 Results - Earnings Call Transcript
02:23pm, Monday, 15'th Aug 2022
SCYNEXIS, Inc. (NASDAQ:SCYX ) Q2 2022 Results Conference Call August 15, 2022 8:30 AM ET Company Participants Debbie Etchison - Communications and IR Dr. Marco Taglietti - President and CEO Christine
Scynexis (SCYX) Reports Q2 Loss, Tops Revenue Estimates
09:47am, Monday, 15'th Aug 2022
Scynexis (SCYX) delivered earnings and revenue surprises of 7.02% and 12.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SCYNEXIS to Report Second Quarter 2022 Financial results and Provide a Corporate Update on August 15
08:30am, Tuesday, 09'th Aug 2022
JERSEY CITY, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistan
